Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model